Macox Plus 600 Tablet is a combination antimicrobial medication containing Rifampicin 600 mg and Isoniazid 300 mg, primarily indicated for the treatment of tuberculosis (TB). Rifampicin acts by inhibiting DNA-dependent RNA polymerase in Mycobacterium tuberculosis, thereby suppressing RNA synthesis and bacterial replication. Isoniazid exerts its bactericidal effect by inhibiting the synthesis of mycolic acids, essential components of the mycobacterial cell wall. The synergistic action of these agents enhances therapeutic efficacy and reduces the risk of drug resistance. Macox Plus 600 is typically administered as part of a multi-drug regimen under strict medical supervision, with dosing tailored according to patient weight, disease severity, and treatment response. Common adverse effects include hepatotoxicity, peripheral neuropathy, gastrointestinal disturbances, and hypersensitivity reactions; therefore, liver function tests and neurological assessments are recommended during therapy. Patients should be advised to avoid alcohol and report any signs of jaundice, persistent nausea, or unusual fatigue promptly. This combination is contraindicated in patients with known hypersensitivity to rifampicin or isoniazid and should be used cautiously in individuals with pre-existing liver disease. Macox Plus 600 Tablet is a critical component in the effective management of tuberculosis, contributing to improved patient outcomes when used appropriately.